Synonyms: EED inhibitor-1 | example 2 [WO2016103155A1] | MAK-683
Compound class:
Synthetic organic
Comment: MAK683 is an allosteric inhibitor of the protein-protein interaction (PPI) between embryonic ectoderm development protein (EED) and polycomb repressive complex 2 (PRC2; EZH2) that was developped by Novartis for potential antineoplastic activity. It is one of the chemical structures claimed in Novartis' patent WO2016103155A1, and it targets EED [1]. EED has no intrinsic enzymatic activity but it is essential for PRC2 function. EED binds to histone H3K27 trimethylation marks which localizes the PRC2 complex to the chromatin substrate and allosterically activates PRC2's methyltransferase activity. Disruption of the EED-EZH2 PPI results in a loss of H3K27me3-stimulated PRC2 activity and reduces histone H3K27 trimethylation. In EZH2-mutated and PRC2-dependent cancer cells this PPI disruption modifies gene expression patterns within cancer pathways and ultimately decreases tumour cell proliferation.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|